Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;18(19):2433-2443.
doi: 10.2217/fon-2021-1488. Epub 2022 Apr 20.

Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer

Hong-Shuai Li  1 , Cheng-Ming Liu  2 , Yan Wang  1
Affiliations
Review

Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer

Hong-Shuai Li et al. Future Oncol. 2022 Jun.

Abstract

The success of sotorasib (AMG-510) and adagrasib (MRTX-849) has resolved the problem of non-availability of drugs for patients with KRASG12C-mutated non-small-cell lung cancer. However, more research is required before these drugs can be introduced as a first-line treatment for those patients, and there are no available drugs for other non-G12C-mutated patients so far; therefore, immunotherapy remains the optimal first-line treatment in this situation. The role of KRAS in affecting the response to immunotherapy in non-small-cell lung cancer has not been fully elucidated. The purpose of this review was to summarize the impact of KRAS mutations, a highly heterogeneous group, on immunotherapy to provide clinicians and researchers with relevant information that can help guide decision-making.

Keywords: KRAS; co-mutation status; immunotherapy; mutation subtypes; non-small-cell lung cancer.

Plain language summary

Sotorasib (AMG-510) and adagrasib (MRTX-849) have changed the problem of non-availability of targeted drugs for patients with KRAS-mutated lung cancer. However, thus far, immunotherapy remains the optimal treatment for lung cancer patients with KRAS mutations who have not received previous treatment. The role of KRAS in affecting the response to immunotherapy in non-small-cell lung cancer has not been fully elucidated. The purpose of this review was to summarize the impact of KRAS mutations, a highly heterogeneous group, on immunotherapy to provide clinicians and researchers with relevant information that can help guide decision-making.

PubMed Disclaimer